Forest Laboratories — Proxy Contest (August 2011)
9 slides from Forest Laboratories's proxy contest presentation, Aug 1, 2011
Slide 1: Schedule 14A - Forest Laboratories, Inc.
SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted
Slide 2: Schedule 14A filing fee information
4) Proposed maximum aggregate value of transaction: 5) Total fee paid: ¨ Fee paid previously with preliminary materials. ¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the pre
Slide 3: Participants filed definitive proxy statement on July 19, 2011
ON JULY 19, 2011, THE PARTICIPANTS (AS DEFINED BELOW) FILED A DEFINITIVE PROXY STATEMENT WITH THE SECURITIES AND EXCHANGE COMMISSION. SECURITY HOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY CARL C. ICAHN, DR. ALEXANDER J. DENN
Slide 4: Icahn 2011 July Response to ISS
Icahn2011 July Response to ISS
Slide 5: Summary
Summary •We Ende 2•This facesenjoyed to presentation theOverview board meeting of is directors inwith response ISS totodiscuss your request the current for additional situation at material Forest regarding Laboratories Bebchuk and ourand ability Ende’sto help relevant the company experiences navigat
Slide 6: Bebchuk's Issue and Relevant Experience
Bebchuk’s Issue Lack Nomination Lead Flawed Potential Place Program Compensation •Relevant 3“Paying A Heads Renowned Member Legal Prepared Bebchuk leading of director at Bebchuk expertise pay Forest adequate the for Experience Solution of aserved background authority Harvard Long-Term arrangements,
Slide 7: Ende Issue and Relevant Experience
Ende Issue Entrenched lacking Negative due Myriad Lack Unproven Potential Initiation retained 4•Relevant Audit Board Helped Risk Ende toof will atOversight looming worked helped evaluated Committee independence legal Forest contained focus units re-focus GENZ Solution operating and add business boar
Slide 8: Ende's Financial, Operating and Drug Experience
•- Acquisitions 5Ende’s Financial Operating Drug During Ende Ende’smarkets worked understands experience experiences experience that statements leverage time, and as - Competitive adivestitures as Ende senior what as as -aa-Clinical aresearch Corporate Genzyme medical analyzed factors biotechnology
Slide 9: Forest Labs will benefit from all Icahn nominees
Forest •Bebchuk’s regulatory •Ende’s 6We would Labs experiences greatly authorities experiences will benefit appreciate as afrom as Genzyme a Harvard your all Icahn support director, Law nominees of School research Denner, serving Professor analyst Mulligan, as directors and andBebchuk Norilsk medic